

## Articles in 2019 with ADx involvement

1. [The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?](#)  
Fichou Y, Al-Hilaly YK, Devred F, Smet-Nocca C, Tsvetkov PO, Verelst J, Winderickx J, Geukens N, **Vanmechelen E**, Perrotin A, Serpell L, Hanseeuw BJ, Medina M, Buée L, Landrieu I.  
*Acta Neuropathol Commun.* 2019 Mar 1;7(1):31. doi: 10.1186/s40478-019-0682-x.
2. [Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults.](#)  
Schaeverbeke J, Gille B, Adamczuk K, **Vanderstichele H**, Chassaing E, Bruffaerts R, Neyens V, **Stoops E**, Tournoy J, Vandenberghe R, Poesen K.  
*J Neurochem.* 2019 Apr;149(1):139-157. doi: 10.1111/jnc.14680. Epub 2019 Mar 20
3. [Plasma amyloid  \$\beta\$  40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.](#)  
Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, **Vanmechelen E**, **De Vos A**, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).  
*Alzheimers Dement.* 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18
4. [Antibody-based methods for the measurement of  \$\alpha\$ -synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.](#)  
Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, **Stoops E**, **Vanderstichele H**, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.  
*J Neurochem.* 2019 Apr;149(1):126-138. doi: 10.1111/jnc.14569. Epub 2018 Nov 13.
5. [Pre-analytical stability of novel cerebrospinal fluid biomarkers.](#)  
Willemsen EAJ, Vermeiren Y, Garcia-Ayllon MS, Bridel C, De Deyn PP, Engelborghs S, van der Flier WM, Jansen EEW, Lopez-Font IB, Mendes V, Manadas B, de Roeck N, Saez-Valero J, Struys EA, **Vanmechelen E**, Andreasson U, Teunissen CE.  
*Clin Chim Acta.* 2019 Oct;497:204-211. doi: 10.1016/j.cca.2019.07.024. Epub 2019 Jul 23
6. [Parkinson's disease biomarkers based on  \$\alpha\$ -Synuclein](#)  
Muneera Fayyad, Safa Salim, Nour Majbour, Daniel Erskine, **Erik Stoops**, Brit Mollenhauer, Omar M. A. El-Agnaf  
*J Neurochem.* 2019 Sep;150(5):626-636. doi: 10.1111/jnc.14809. Epub 2019 Jul 28
7. [CERTIFICATION REPORT: The certification of Amyloid  \$\beta\$ 1-42 in CSF in ERM®-DA480/IFCC, ERM®-DA481/IFCC and ERM®-DA482/IFCC](#)  
Julia Kuhlmann, Sébastien Boulo, Ulf Andreasson, Maria Bjerke, Josef Pannee, Jean Charoud-Got, Guy Auclair, Stéphane Mazoua, Stefanie Trapmann, Heinz Schimmel, Hendrik Emons, Doris Florian, Milena Quaglia, Erik Portelius, Magdalena Korecka, Leslie M. Shaw, Mary Lane, Erin Chambers, **Hugo Vanderstichele**, **Erik Stoops**, Andreas Leinenbach, Tobias Bittner, Rand G. Jenkins, Vesna Kostanjavecki, Piotr Lewczuk, Henrik Zetterberg, Ingrid Zegers, Kaj Blennow
8. [Cerebrospinal Fluid Total and Phosphorylated  \$\alpha\$ -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.](#)  
Schmitz M, Villar-Piqué A, Llorens F, Gmitterová K, Hermann P, Varges D, Zafar S, Lingor P, **Vanderstichele H**, **Demeyer L**, **Stoops E**, Trojanowski JQ, Lee VM, Zerr I  
*Mol Neurobiol.* 2019 May;56(5):3476-3483. doi: 10.1007/s12035-018-1313-4. Epub 2018 Aug 22



9. [Ultrasensitive Detection of Plasma Amyloid- \$\beta\$  as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.](#)  
Chatterjee P, Elmi M, Goozee K, Shah T, Sohrabi HR, Dias CB, Pedrini S, Shen K, Asih PR, Dave P, Taddei K, **Vanderstichele H**, Zetterberg H, Blennow K, Martins RN,  
*J Alzheimers Dis.* 2019;71(3):775-783. doi: 10.3233/JAD-190533.
10. [Brain A \$\beta\$  load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD.](#)  
Vergallo A, Houot M, Cavedo E, Lemercier P, **Vanmechelen E**, **De Vos A**, Habert MO, Potier MC, Dubois B, Lista S, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI),  
*Alzheimers Dement.* 2019 Oct;15(10):1274-1285. doi: 10.1016/j.jalz.2019.07.001.
11. [APP-derived peptides reflect neurodegeneration in frontotemporal dementia.](#)  
Illán-Gala I, Pegueroles J, Montal V, Alcolea D, Vilaplana E, Bejanin A, Borrego-Écija S, Sampedro F, Subirana A, Sánchez-Saudinós MB, Rojas-García R, **Vanderstichele H**, Blesa R, Clarimón J, Antonell A, Lladó A, Sánchez-Valle R, Fortea J, Lleó A.  
*Ann Clin Transl Neurol.* 2019 Dec;6(12):2518-2530. doi: 10.1002/acn3.50948. Epub 2019 Dec 2.
12. [Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease.](#)  
Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, **Dewit N**, **Vanbrabant J**, **Jacobs D**, **Vanderstichele H**, **Vanmechelen E**; Alzheimer's Disease Neuroimaging Initiative (ADNI), Worley P.  
*Alzheimers Dement (N Y).* 2019 Dec 9;5:871-882. doi: 10.1016/j.trci.2019.11.002. eCollection 2019.